



This is the author's version of a work that was accepted for publication in the following source:

Thevathasan, W., B. Debu, T. Aziz, B. R. Bloem, C. Blahak, C. Butson, V. Czernecki, T. Foltynie, V. Fraix, D. Grabli, C. Joint, A. M. Lozano, M. S. Okun, J. Ostrem, N. Pavese, C. Schrader, C. H. Tai, J. K. Krauss, and E. Moro. 2017. Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review. *Movement disorders : official journal of the Movement Disorder Society*: 10-20.

doi: [10.1002/mds.27098](https://doi.org/10.1002/mds.27098)

Notice: Changes introduced as a result of publishing processes such as copy-editing and formatting may not be reflected in this document. For a definitive version of this work, please refer to the published source.

The final publication is available at:

<https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.27098>

Copyright of this article belongs to: © 2017 International Parkinson and Movement Disorder Society

Pedunculopontine Nucleus Deep Brain Stimulation in Parkinson's Disease: A Clinical Review

Wesley Thevathasan, DPhil, FRACP,¹ Bettina Debu, PhD,² Tipu Aziz, FRCS,³ Bastiaan R. Bloem, MD, PhD,⁴ Christian Blahak, MD,⁵ Christopher Butson, PhD,⁶ Virginie Czernecki, PhD,⁷ Thomas Foltynie, PhD, FRCP,⁸ Valerie Fraix, MD, PhD,² David Grubli, MD, PhD,⁹ Carole Joint, RN, PhD,³ Andres M. Lozano, MD, PhD,¹⁰ Michael S. Okun, MD,¹¹ Jill Ostrem, MD,¹² Nicola Pavese, PhD, FRCP,^{13,14,15} Christoph Schrader, MD,¹⁵ Chun-Hwei Tai, MD,¹⁶ Joachim K. Krauss, MD,¹⁷ and Elena Moro, MD, PhD,^{2*} on behalf of the Movement Disorders Society PPN DBS Working Group in collaboration with the World Society for Stereotactic and Functional Neurosurgery

¹Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Australia and the Bionics Institute of Australia, Melbourne, Australia

²Movement Disorders Center, Division of Neurology, Centre Hospitalier Universitaire (CHU) Grenoble, Grenoble Alpes University, Grenoble, France

³Department of Neurosurgery, John Radcliffe Hospital, University of Oxford, Oxford, UK

⁴Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands

⁵Department of Neurology, Universitätsmedizin Mannheim, University of Heidelberg, Heidelberg, Germany

⁶Department of Bioengineering, Scientific Computing and Imaging Institute, University of Utah, Salt Lake City, USA

⁷Department of Neurology, Institut de Cerveau et de la Moelle épinière, Sorbonne Universités, University Pierre-and-Marie-Curie (UPMC) Université, Paris, France

⁸Sobell Department of Motor Neuroscience, University College London (UCL) Institute of Neurology, United Kingdom

⁹Department of Neurology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France

¹⁰Department of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, Canada

¹¹Departments of Neurology and Neurosurgery, University of Florida Center for Movement Disorders, Gainesville, Florida, USA

¹²Department of Neurology, UCSF Movement Disorder and Neuromodulation Center, University of California, San Francisco, USA

¹³Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK

¹⁴Department of Clinical Medicine, Centre for Functionally Integrative Neuroscience, University of Aarhus, Aarhus, Denmark

¹⁵Department of Neurology, Hannover Medical School, Hannover, Germany

¹⁶Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan

¹⁷Department of Neurosurgery, Hannover Medical School, Hannover, Germany

ABSTRACT: Pedunculopontine nucleus region deep brain stimulation (DBS) is a promising but experimental therapy for axial motor deficits in Parkinson's disease (PD), particularly gait freezing and falls. Here, we summarise the clinical application and outcomes reported during the past 10 years. The published dataset is limited, comprising fewer than 100 cases. Furthermore, there is great variability in clinical methodology between and within surgical centers. The most common indication has been severe medication refractory gait freezing (often associated with postural instability). Some patients received lone pedunculopontine nucleus DBS (unilateral or bilateral) and some received costimulation of the subthalamic

nucleus or internal pallidum. Both rostral and caudal pedunculopontine nucleus subregions have been targeted. However, the spread of stimulation and variance in targeting means that neighboring brain stem regions may be implicated in any response. Low stimulation frequencies are typically employed (20–80 Hertz). The fluctuating nature of gait freezing can confound programming and outcome assessments. Although firm conclusions cannot be drawn on therapeutic efficacy, the literature suggests that medication refractory gait freezing and falls can improve. The impact on postural instability is unclear. Most groups report a lack of benefit on gait or limb akinesia or dopaminergic medication requirements. The key

*Corresponding author: Dr. Elena Moro, Centre Hospitalier Universitaire de Grenoble, Grenoble Alpes University, BP217 38043 Grenoble CEDEX 09 France; emoro@chu-grenoble.fr

Members of the MDS PPN DBS Working Group are listed in the Appendix.

Funding agency: The Movement Disorders Society PPN DBS working group in collaboration with the World Society for Stereotactic and Functional Neurosurgery was supported by an unrestricted educational grant from Medtronic.

Relevant conflicts of interests/financial disclosures: The Movement Disorders Society PPN DBS working group in collaboration with the World Society for Stereotactic and Functional Neurosurgery was supported by an unrestricted educational grant from Medtronic.

Received: 26 October 2016; **Revised:** 8 June 2017; **Accepted:** 14 June 2017

Published online 28 September 2017 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.27098

question is whether pedunculopontine nucleus DBS can improve quality of life in PD. So far, the evidence supporting such an effect is minimal. Development of pedunculopontine nucleus DBS to become a reliable, established therapy would likely require a collaborative effort between experienced centres to clarify biomarkers

predictive of response and the optimal clinical methodology. © 2017 International Parkinson and Movement Disorder Society

Key Words: deep brain stimulation; gait freezing; Parkinson's disease; pedunculopontine nucleus

The pedunculopontine nucleus (PPN, also known as the pedunculopontine tegmental nucleus or PPTg) is a collection of heterogeneous neurons at the junction of the midbrain and pons (Figure 1).^{1,2} PPN neurons express a range of neurotransmitters but perhaps most prominently acetylcholine.² The PPN displays substantial reciprocal connectivity with the cortex via the thalamus, basal ganglia, and spinal cord (Figure 2).³ A long and rich history of research in animals suggests that the PPN may affect locomotion, the startle response, states of arousal, and even reward.⁴⁻⁸ Of relevance to gait, the PPN has been considered a key component of the mesencephalic locomotor region—an area where electrical stimulation in decerebrated animals can induce locomotor-like activity, although the relevance of this concept to the therapeutic impact of PPN DBS is debated.^{2,3}

PPN DBS has developed as an experimental therapy for axial motor deficits in Parkinson's disease (PD), particularly those that are poorly responsive to subthalamic nucleus (STN) and globus pallidus internus (GPi) DBS.⁹⁻¹¹ Axial deficits such as gait freezing and postural instability are major contributors to impaired quality of life in PD. The initial emergence of PPN DBS, therefore, raised much excitement. However, it became apparent that the therapeutic outcomes from PPN DBS were variable and often disappointing, both within and between surgical centres.¹²⁻¹⁶ This variability may reflect a fundamental limitation of the target or alternatively that the methodology has not been optimized yet.

To try and progress the field, a working group was approved as a bisocietal endeavour of the international Movement Disorders Society and the World Society for Stereotactic and Functional Neurosurgery. This group encompasses neurologists, neurosurgeons, neurophysiologists, neuropsychologists, and electrical engineers with expertise on the PPN and/or PPN DBS. The initial objective was to summarise, analyse, and publish on the state of the field.

The surgical aspects of this work (surgical anatomy and techniques) have been recently published in a specialized neurosurgical journal.^{17,18} This article deals with medical aspects of PPN DBS, including the clinical application and outcomes to date.

Methods

Literature Search

The PubMed database was searched from 1990 to March 2017 using the following key words: deep brain stimulation, Parkinson's disease, pedunculopontine nucleus, surgery, treatment. Only publications in English reporting clinical outcomes of Pedunculopontine nucleus deep brain stimulation (PPN DBS) in PD were selected.

Questions and Consensus Process

The Executive Committee of the Working Group formulated several questions which were distributed to groups of authors according to their expertise, as with previous task forces.^{19,20} The answers were organized into the manuscript and reviewed by the executive committee and the complete task force at multiple international meetings. Areas of disagreement were discussed and modified according to Delphi techniques until consensus was reached.²¹ The literature was updated during the work.

Results

Fewer than 100 cases with PD implanted with PPN DBS have been published.^{9,10,12-16,22-27} Between and even within surgical centers, there has been substantial variation and often evolution in clinical methodology. Therefore, we must acknowledge the many limitations and confounds from these reports. First, the clinical application of PPN DBS employed so far does not necessarily reflect the optimal methodology. Second, the location of where therapeutic effects from stimulation arise has not been established yet. For example, electrodes have been implanted in both rostral and caudal PPN subregions.^{25,26} Furthermore, in some cases, stimulation may actually have been directed at networks involving neighboring structures including the cuneiform and peripeduncular nuclei.^{27,28} In any case, the range of stimulation parameters typically employed means that a range of networks may be implicated in any response.^{24,28} For example, the differing stimulation frequencies applied to the PPN (10 to 80 Hz) may affect the selectivity of neural elements.²⁹ For this reason, we always imply stimulation of the PPN

region when we discuss PPN DBS. Third, the limited and heterogeneous dataset prevents us drawing firm conclusions regarding the scope of clinical impact. This dataset includes case reports, open label series, double-blinded single time point assessments, and longer term double-blinded studies (Table 1). Finally, PPN DBS has evolved as a treatment for axial motor impairment, particularly gait freezing and falls. The impact of PPN DBS on other domains has generally been reported as incidental observations.

Clinical Application

Indication

After initial reports suggested improvement in gait freezing from PPN DBS in PD, the typical indications became medication refractory gait freezing and falls.^{9,12-14,16} Therefore, most patients implanted with PPN DBS have fallen into 1 of the following 2 groups:

1. Patients with PD who exhibit early and severe gait freezing resistant to medication as the dominant cause of disability are candidates for lone PPN DBS.³⁰ This is an unusual subgroup, perhaps comprising around 5% of patients with PD.³⁰ Indeed, some of these patients may later declare features of an atypical parkinsonian disorder.³¹ Patients with medication responsive freezing and motor fluctuations are candidates for established therapies such as STN or GPi DBS.^{32,33}
2. Patients with PD who develop medication resistant gait freezing during STN or GPi DBS can be candidate for PPN DBS.^{12,15,22,25} However, costimulation of both the PPN and STN/GPi could cause an interaction between stimulation at these sites.³⁴ This could be synergistic, with STN or GPi DBS adding improvement to akinesia and “off” freezing compared with lone PPN DBS.²² However, high-frequency STN or GPi DBS could transmit to the PPN via their extensive reciprocal connections and counteract PPN DBS.^{2,7,35}

Target Selection

The exact location and the anatomical boundaries of the PPN are controversial.³⁶⁻³⁸ Furthermore, the precise location of stimulation in the brain stem is poorly reflected by commissural coordinates. Therefore, some studies have reported the location of PPN stimulation relative to local landmarks. A detailed discussion on the surgical anatomy and targeting is found in our companion papers.^{17,18} The next 2 issues are raised as important for understanding the medical management of PPN DBS.

Rostral vs Caudal PPN Stimulation. Over time, 2 topographic regions of the PPN have been posited,

TABLE 1. Studies of at least 5 patients that have specifically measured the impact of PPN DBS on gait freezing and falls

Study: Author, Date	Centre(s)	Number of patients	PPN DBS type	PPN DBS frequency	Follow up duration	Study design	Outcome measures	Gait and falls Outcomes
Ferraye et al, 2009 ¹²	Grenoble	6	Bilateral rostral with STN DBS	15-25Hz	12 months	Double blind	UPDRS part II, FOGQ, Freezing duration	Reduced FOG in 4/6 patients.
Moro et al, 2010 ¹³	Toronto	6	Unilateral rostral lone PPN DBS	50-70Hz	12 months	Double blind	UPDRS part II	Reduced falls in 1/6 patients. Reduced falls in all patients.
Thevathasan et al, 2011 ¹⁴	Brisbane	5	Bilateral caudal lone PPN DBS	35Hz	24 months	Open label	GFQ and FOGQ	Reduced FOG in 5/6 patients at 3 months and 3/6 patients at 12 months Reduced FOG and falls in all 5 patients at 6 months and 2 years (but lesser benefit at 2 years)
Thevathasan et al, 2012 ³⁷	Oxford and Brisbane	7	Bilateral caudal lone PPN DBS	35-40Hz	2-30 months	Single session double blind	Duration of FOG on gait analysis	Significant improvement in FOG off medication.
Welter et al, 2015 ¹⁶	Paris	6	Bilateral rostral and caudal lone PPN DBS	20-40Hz	6 months	Double blind	UPDRS part II, RSGE, Gait initiation from a force platform	Bilateral DBS better than unilateral One patient required device removal due to infection. One patient sustained a brainstem bleed. Of the remaining 4 patients -reduced FOG in 3 and reduced falls in 2
Mestre et al, 2016 ⁴²	Toronto	8	Unilateral rostral lone PPN DBS	70Hz	24-48 months	Double blind	UPDRS part II	Reduced falls at 2 years in 6/8 patients and at 4 years in 4/6 patients. Reduced FOG at 2 years in 5/8 patients and at 4 years in 4/6 patients.

UPDRS, Unified Parkinson's Disease Rating Scale; GFQ, gait and falls questionnaire; FOGQ, freezing of gait questionnaire; RSGE, rating scale for gait evaluation; FOG, freezing of gait.




FIG. 1. Three axial sections through the human brain stem showing the position of the PPN. The level of the 3 sections is indicated by the dashed lines in the para-sagittal cartoon of the brain stem. RN, red nucleus; PPN, pedunclopontine nucleus; SN, substantia nigra. Adapted from Olszewski and Baxter (1954). Figure adapted from Jenkinson et al.²

rostral and caudal. Studies have reported spatially segregated patterns of local field potentials recorded from PPN electrodes in patients with PD. Alpha band oscillations in the caudal subregion (around 4 mm below the pontomesencephalic junction) were reported to correlate with gait and freezing,³⁷ whereas beta band oscillations in the rostral subregion (around the level of the inferior colliculus) were not found to correlate with gait (real or imagined).^{37,39} Two studies reported very limited clinical data that further raised the hypothesis that caudal PPN DBS may be more effective than rostral PPN DBS for gait freezing.^{37,40} Given the surgical trajectory usually runs along the long axis of the PPN, it is feasible to target both subregions with the same electrode giving the option to activate either.

Unilateral vs Bilateral PPN Stimulation. The relative efficacy of unilateral versus bilateral PPN stimulation is controversial. Some practitioners elected to implant unilaterally, given the bilateral connectivity of each PPN and the greater risks inherent in bilateral implantation.^{2,13} In a small, double-blind study employing

spatiotemporal gait analysis, bilateral PPN stimulation in 7 patients was reported as more effective than unilateral PPN stimulation for “off medication” gait freezing.⁴¹ In addition, some patients implanted with unilateral PPN DBS have been reported to further benefit from contralateral PPN implantation.⁴²

Outcome Assessments

A common method to assess outcomes has been the Unified Parkinson’s Disease Rating Scale (UPDRS).⁴³ The “pull test” item of the UPDRS was the only method used in most studies to assess postural instability; however, this test is said to suffer poor reliability and scaling (score 4).⁴⁴ Gait freezing exhibits substantial fluctuation which makes accurate measurement difficult. Some studies of PPN DBS employed specific instruments to capture gait freezing such as the Gait and Falls Questionnaire (GFQ, score 64), and the Freezing of Gait Questionnaire (score 24).^{45,46} Even fewer studies employed objective laboratory methods including spatiotemporal gait analysis using a walkway with




FIG. 2. Schematic illustration of the connectivity of the PPN. Distinct functional types of PPN subpopulations innervate basal ganglia and in turn basal ganglia structures project back to different neuronal populations in the PPN. It is important to note that projections from the PPN to the structures illustrated here are not wholly independent: cholinergic and noncholinergic neurons from topographically distributed populations send collaterals to several structures (eg, to thalamus and basal ganglia). Likewise, descending collaterals of ascending axons contribute to a dense innervation of structures in the lower brain stem, pons, medulla, and spinal cord. Figure adapted from Gut et al.³

embedded pressure sensors, step tracking with shoe mounted pressure sensors, and fast Fourier transformation of trunk accelerometer data.^{12,37,41} However, such laboratory methods can be confounded by the propensity of freezing to disappear under observation.⁴⁷ Some studies therefore employed potent triggers of gait freezing such as turning on the spot in a confined space.^{12,41} Individual studies have attempted to assess nonmotor deficits such as sleep, cognition, psychiatric state, quality of life, and adverse events using instruments commonly used to assess DBS in PD.⁴⁸

Postoperative Management

Programming. Titration of PPN DBS can be complex and time consuming. Factors include the fluctuating nature of gait freezing, the unpredictable degree of benefit, and the prolonged latencies (days to weeks) reported for benefits to emerge.¹²⁻¹⁴ Furthermore, an acute microlesion or “stun” effect has been described where gait freezing improves in the early postoperative period prior to activation of stimulation.^{16,37,49}

The major stimulation variables explored have been stimulation location along the electrode (see previous

discussion of rostral vs caudal DBS) and frequency. Other reported parameters have been fairly restricted (eg, typical pulse width range 60-90 μ sec,^{13,35} and voltage range from 0.8 to 3.6 V) with monopolar or bipolar configuration.^{12,13,23}

All studies have reported that low frequencies (<80 Hz) of PPN DBS seem optimal for motor deficits. Studies of bilateral PPN DBS have reported that 20 to 35 Hz stimulation was useful for gait freezing.^{12,14,22,23} One study found that patients responded best to higher frequencies (60-80 Hz).¹³ This study differed in 2 critical respects: the use of unilateral rather than bilateral PPN DBS and the additional goal of treating comorbid postural instability.¹³ Two studies have specifically investigated frequency effects of PPN DBS in PD. One study explored differing very low frequencies (5-35 Hz) on reaction time.²³ This study found that 20-35 Hz PPN DBS was superior to 5 Hz and 10 Hz stimulation.²³ Another study directly compared the impact of bilateral low frequency (10-25 Hz) versus higher frequency (60-80 Hz) PPN DBS on gait freezing, akinesia, and sleepiness.³⁵ Of 9 patients, 7 had less gait freezing with low-frequency PPN DBS.³⁵ Bilateral higher frequency PPN DBS was associated with worsened akinesia and sleepiness.

Titration of Medication and Stimulation of Other Targets. The lack of benefit of PPN DBS on akinesia (see later) has meant that either dopaminergic medication or costimulation of conventional targets (STN or GPi) has been required to maintain the “on” state.^{12,14} PPN DBS has not been widely reported to substantially change dopaminergic medical requirements. In some patients, an ideal motor benefit was achieved by reducing the high frequencies normally employed in the STN (eg, from 130 Hz to 80 Hz) during costimulation of the PPN.^{15,50} Even with lone STN DBS, it has been reported that lower stimulation frequencies may improve “on” freezing, so it is unclear if this represents a specific interaction between the 2 stimulation locations.⁵¹

Stimulation and Implantation Side Effects. Reversible side effects resulting from PPN region DBS or the microlesion effect from implantation likely relate to involvement of neighboring structures.¹⁷ These include the following:

1. Sensory phenomena. Contralateral paraesthesia likely reflects current spread to the medial lemniscus.^{12,22,52} This typically habituates over seconds to minutes. A more profound and even painful sensation may reflect spread into the more lateral spinothalamic tract.⁵² In a single case, stimulation caused ipsilateral pain consistent with spread to the trigeminal nucleus.⁵³
2. Oscillopsia. Typically, reported by patients as “shimmering” vision. Infrared eye tracking demonstrates nystagmus at the frequency of DBS ipsilateral to stimulation. Stimulation of fibers in the

uncinate fasciculus of the cerebellum and the superior cerebellar peduncle (which in turn stimulate the saccadic premotor neurones) is hypothesized.⁵⁴

3. Limb myoclonus. This may reflect involvement of the ipsilateral cerebellar peduncle/decussation.¹²
4. Urge urinary incontinence with phasic detrusor over activity. This was described in a patient from the time of implantation and that recovered over months.⁵⁵ The nearby pontine micturition centre was implicated.⁵⁵

Outcomes

Motor Impact

Gait Freezing: Short Term (<2 Years). Reduced gait freezing appears to be the major therapeutic benefit of PPN DBS, evident from the earliest reports.^{9,24} However, the evidence base remains modest, with studies being small (up to 10 patients) and ranging from unblinded open-label series to double-blinded studies with controls (Table 1).^{12-16,41} These studies suggest that PPN DBS can improve gait freezing in some patients, in both off and on medication states.^{13,41} Two surgical centers (Toronto and Grenoble) employed unilateral or bilateral stimulation to the rostral PPN and reported variable and overall modest improvements.^{12,13} Another 2 surgical centres (Oxford and Brisbane), applied bilateral stimulation to the caudal PPN region and also reported modest but more substantial benefits.^{14,41} Two more surgical centers (Rome and Bristol) reported that PPN DBS improved motor function including gait, but did not isolate gait freezing as a separate outcome measure.^{15,50,56,57} There are also single case reports of PPN DBS in PD with overall mixed results.^{25,26}

Some inferences regarding the degree of efficacy of PPN DBS on freezing can be attempted by using selected studies that reported scores from individual patients.^{12-14,41} Pooled results from 3 studies that reported individual scores for item 14 (freezing) of the UPDRS part II, revealed an overall improvement with PPN DBS of 30% (N = 15, mean score 2.2/4 reduced to 1.5/4) when on medication.^{12,13,16} The results of patients from 2 centers assessed with the GFQ (reflecting function while medicated) revealed an improvement of 39% (N = 7, mean 45.7 to 27.7).⁵⁸ One double-blind controlled study assessed freezing using spatiotemporal gait analysis while off medication and reported an overall 64.6% improvement (N = 7, freezing duration 31.1 to 11.0 seconds).⁴¹ Thus, so far PPN DBS has been reported to partially improve, but not abolish gait freezing. Whether such partial benefits are clinically meaningful is unclear but perhaps captured in quality of life assessments (see later). Furthermore, there is insufficient data to comment on

whether PPN DBS differentially affects all the various aspects of gait freezing that have been described.

Gait Freezing: Longer Term (>2 Years). One recent paper reported the outcomes at 4 years after unilateral PPN DBS implantation in 6 patients with PD, with double-blinded assessments off and on stimulation (2 weeks in each condition).⁴² There was persistent benefit in 4 of the 6 patients on gait freezing and falls.

Other Aspects of Gait. Two studies suggested that PPN DBS could alter a variety of spatiotemporal parameters during unconstrained gait, that is, when walking freely straight ahead.^{57,59} However, these studies had methodological issues, including a set order of conditions, unblinded assessments, the potential influence of fluctuating medication state, and washout of STN DBS.⁵⁹ In contrast, in a double-blinded controlled study employing spatiotemporal gait analysis, the impact of lone PPN DBS on gait was assessed when off medication.⁴¹ This study reported a benefit of PPN DBS on gait freezing. During unconstrained walking, patients with freezing had reduced step length and increased step length variability when compared with patients without freezing. However, these deficits were unchanged by PPN DBS.⁴¹ This study suggests that the impact of PPN DBS differs from that of levodopa and STN DBS, which improve step length and thereby presumably also improve off medication freezing.^{47,60} Therefore, the therapeutic benefits of PPN and STN DBS (or levodopa) on gait would be predicted to be complementary although this remains to be formally tested.

Balance. The impact of PPN DBS on overall balance is uncertain. Improved postural instability was specifically cited as a potential benefit in one of the earliest reports of PPN DBS.⁹ However, few studies have specifically isolated the impact on postural instability, and any benefit has been variable and often not detected.^{9,12,13,16} One issue may be the shortcomings in the assessment tool for postural instability used by these studies—the clinical “pull test” (item 30 of the UPDRS part III and item 3.12 of the MDS-UPDRS, score/4).^{43,61} The pull test may not be sufficiently sensitive or reliable to detect a clinically meaningful change.^{14,44} Another issue may relate to DBS programming as it has been suggested that different frequencies of stimulation may be needed to improve postural instability when compared with gait freezing.³⁵ Further research is needed into this area.

Two recent papers suggest that other aspects of balance may be modulated by PPN DBS.^{16,27} In these studies, PPN DBS appeared to alter measures of postural sway in center of pressure during stance.¹⁶ In one study, PPN DBS improved anticipatory postural adjustments.¹⁶ In another study, PPN DBS (during STN stimulation) appeared to improve vestibular perceptual thresholds.²⁷ The net functional consequences of such effects remain to be established.

Falls. An improvement in falls frequency with PPN DBS has been documented using item 13 of the UPDRS part II (score/4), components of the Rating Scale for Gait Evaluation and the GFQ, and patient diaries.^{12-14,16,23,42} Fewer falls with PPN DBS has been a consistently reported therapeutic benefit, occurring even in studies where any benefit on freezing or postural instability was modest or not found.^{13,23} This could reflect that falls frequency is a more certain and sensitive biomarker of the response to PPN DBS. It is unclear if falls are reduced because of less freezing, less postural instability, or another mechanism (eg, a paradoxical reduction in falls because of less ambulation or greater use of gait aids has not been excluded). In 2 studies, reduced falls were unrelated to freezing, which suggests that the effect is somewhat independent of any reduction in gait freezing.^{13,23} The benefit of PPN DBS on falls is reported to endure for the long term in 1 study.⁴²

Axial Deformity. Two reports describe an apparent benefit of unilateral PPN DBS on Pisa syndrome. In 1 report, the electrode was contralateral to the side of lateral lean and improvement was sustained over 14 months and documented with videotape assessment.⁶² In the other report, the electrode was ipsilateral to the side of lateral lean and improvement wore off over 3 years. The effect in this case was documented with a wall-mounted goniometer.⁶³ Such findings seem to mirror the debate regarding whether the direction of lean in Pisa syndrome relates to the side most affected by parkinsonism.⁶⁴

Speech. A total of 3 studies have specifically assessed the impact of PPN DBS on speech.⁶⁵⁻⁶⁷ In an initial study, unilateral PPN DBS was suggested to improve oromotor movements, raising hopes that speech could improve.⁶⁵ However, a recent double-blinded study of 6 patients found that bilateral PPN DBS worsened measures of phonation time and speech diadokokinesis with overall mixed effects on speech intelligibility.⁶⁷ Considering the current evidence, it is not clear whether the overall impact of PPN DBS on speech is helpful or detrimental.

Akinesia, Rigidity, and Tremor. Almost all studies of PPN DBS have observed no substantial benefit on akinesia, rigidity, or tremor as assessed by items 1 to 26 of the UPDRS part III.^{12-14,22} However, 1 group has consistently reported a possible benefit of PPN DBS on these items, both off and on medication.^{9,15,50,56} These patients were generally also receiving STN DBS, raising the possibility that persistent washout effects could have influenced the results. Furthermore, PPN DBS does not significantly change dopaminergic medication requirements, and there is additional motor benefit following STN DBS.^{12,22} PPN DBS does not uniformly yield the type of reaction time benefits that are reported with levodopa and

STN and pallidal DBS.^{23,58,68,69} Furthermore, double-blinded spatiotemporal gait analysis has revealed no change to step length with PPN DBS.⁴¹ Importantly, in 1 double-blind study, bilateral PPN DBS applied at medium frequencies (60-80 Hz) significantly worsened akinesia scores when compared with low-frequency stimulation (15-25 Hz).^{7,35,70}

Reaction Time. Studies of at least 8 patients that assessed the impact of PPN DBS on reaction time have reported a benefit most prominent in simple reaction time tasks.^{23,58,71} This reaction time benefit was reported to affect the entire reaction time distribution curve and not just outliers, argued to reflect a motor impact rather than augmented attention.²³ A further study suggested that this motor effect could be isolated to enhanced release of preprogrammed motor responses, supported by the absence of the Start React phenomenon in patients with gait freezing that was restored by PPN DBS.⁵⁸

Nonmotor Impact

Cognition and Mood. That the PPN comprises part of the reticular activating system has raised the question of whether PPN DBS may improve attention, especially as attentional deficits are implicated in the pathogenesis of gait freezing.^{72,73} A recent study found that bilateral PPN DBS improved simple reaction times without a warning cue but not a go/no-go or divided attention task.⁷¹ There was a strong trend that PPN DBS also improved simple reaction times with a warning cue ($P = .07$). However, on the basis that this latter result was not significant, the authors argued that PPN DBS improved phasic arousal rather than a motor effect. Although with only 8 patients in the study, this may simply reflect insufficient power. In addition, 2 further studies (discussed in the previous section) suggested that the selective impact of PPN DBS on certain aspects of reaction time is likely a result of enhanced motor performance.^{23,58} Thus, it seems currently that there is insufficient evidence to support that PPN DBS augments alertness or general attention.

Several studies of PPN DBS have performed cross-sectional cognitive assessments. Two studies found no consistent change in the Mattis Dementia Rating Scale or a composite assessment of frontal lobe function in 6 patients with PPN DBS.^{12,16} However, several studies from the Rome group have reported substantial improvements with PPN DBS on frontal lobe cognition in small numbers of patients. For example, 2 such studies suggested improvements in performance on an n-back task and various tasks of executive functioning but with limited information regarding the methodology.^{74,75} One case report claimed that PPN DBS improved measures in all tested cognitive domains including attention, memory, and language and was perhaps modulated by attentional improvements

although this effect may have been a result of intercurrent factors.⁷⁶ These authors also reported that PPN DBS increased prefrontal glucose utilization using Flu-deoxyglucose-PET (FDG-PET) with associated improvements in delayed recall and executive functioning.⁷⁷ However, such frontal changes with PPN DBS were not found on regional cerebral blood flow PET in 3 other studies, where blood flow changes appeared restricted to subcortical and sensorimotor cortical areas.^{15,78,79}

In 1 study of 6 patients, PPN DBS did not consistently change scores of the Beck Depression Inventory or the Starkstein Apathy Scale.¹² In another study of 4 patients, anxiety and depression did not change, as assessed by questionnaires (Brief Anxiety Scale, Montgomery, and Asberg Depression Scale).¹⁶ Other major clinical studies (with ≥ 5 patients) have not formally assessed psychiatric outcomes.^{13,14,22} However, clinically obvious psychiatric effects from PPN DBS were not reported in these studies.

Sleep. Three studies have specifically assessed whether PPN DBS affects sleep in parkinsonian patients.⁸⁰⁻⁸² The results suggest a marked impact on switching between sleep states, particularly the promotion of rapid eye movement (REM) sleep. This is consistent with decades of animal research.⁸³

Two studies assessed patients using overnight polysomnography, and both reported that PPN DBS roughly doubled the proportion of REM sleep.^{80,82} In 1 study of 5 patients with PD or PSP, unilateral PPN DBS increased nightly REM sleep time (mean 35 to 61 minutes) and percentage REM sleep (mean 8% to 14%) compared with no stimulation.⁸² Importantly, this study found that the increased REM sleep was a result of an increased frequency rather than duration of REM sleep episodes. Non-REM sleep was unchanged by PPN DBS. Two patients experienced REM sleep behavioral disturbance, and this persisted with PPN DBS.

The increased REM sleep episodes with PPN DBS suggest that there may be an underlying impact on transitioning between sleep states. In support of this notion, an early study detected phasic potentials during and before REM sleep from PPN electrodes consistent with ponto-geniculo-occipital waves.⁸⁴ One study reported 2 patients in whom PPN DBS could provoke sleep from a state of wakefulness, assessed clinically and with electroencephalography.⁸¹ These patients were alert during low-frequency PPN DBS (10 or 25 Hz). In 1 patient, abrupt withdrawal of this low-frequency PPN DBS reproducibly triggered short periods of REM sleep. In both patients, initiation of high-frequency PPN DBS (80 Hz) could precipitate non-REM sleep.

It is unclear what, if any, functional consequence may result from increased REM sleep with PPN DBS. Some but not all studies suggest that REM sleep may decline in PD.⁸⁵ REM sleep is postulated to improve

memory consolidation, particularly that of procedural learning.⁸⁶ Whether this has mechanistic relevance to the motor impact of PPN DBS is unknown.

Surgical Risks

At this stage, there does not appear to be any contraindication that is specific to PPN DBS relative to other forms of DBS for Parkinson's disease. However, patients would need to be counseled that the occurrence of even a small haemorrhage in the brain stem could have devastating consequences.^{16,67}

Quality of Life

Two double-blinded studies have reported on the impact of PPN DBS on quality of life using the Parkinson's Disease Questionnaire-39 (PDQ-39). One study of 6 patients found that PPN DBS did not consistently change scores of the PDQ-39.¹² However, in 5 of 6 patients, PPN DBS improved scores in the mobility subsection of the PDQ-39.¹² In a second report of 6 patients, 2 patients had severe adverse events (infection requiring device explanation and brain stem hemorrhage). In the remaining 4 patients in that study, quality of life improved significantly.¹⁶

Discussion

Despite more than 10 years of history of the use of PPN DBS in patients with PD, the cohort of implanted patients worldwide remains limited.^{9,10} In addition, only a few centers have generated the bulk of the cases and published literature.^{12-15,22} These factors limit the strength and thus inferences that can be drawn from the dataset.

We have presented a summary of the clinical application of PPN DBS employed to date. Clinical methodologies have varied greatly. For example, in some cases stimulation is even argued to be directed at neighbouring structures including the cuneiform and peripeduncular nuclei.^{36,87} However, it is conceivable that variance in stimulation location could identify a more effective target than the PPN itself. What is evident is that fundamental aspects of the clinical application of PPN DBS remain unclear, including if there are specific biomarkers of response to guide patient selection, the ideal stimulation location and parameters of stimulation. Indeed, these areas could interact together, for example, it is possible that postural instability may benefit from stimulation of a different PPN subregion and with different stimulation parameters compared with gait freezing.¹³

Although acknowledging the limitations of the dataset, the available evidence supports that PPN DBS has the potential to improve gait freezing in both the off and on medication states and can reduce falls in some patients.^{12-14,41} The impact on postural instability is

unclear. The degree of improvement is highly variable both between and within surgical centers. On average, PPN DBS offers a reduction and not resolution of freezing and falls. There is no known preoperative factor that predicts such benefits. The variability of benefit may reflect the differing clinical methods employed. For example, it is difficult to compare outcomes of patients implanted with lone PPN DBS when compared with those also receiving stimulation in other targets (often with reciprocal connections to the PPN). In addition, axial deficits are difficult to capture with the available clinical scales and more objective measures are needed.⁴⁴ For example, the consistent benefit of PPN DBS on falls across studies may simply reflect that it is an unambiguous and sensitive biomarker of response. Furthermore, it should be acknowledged that disease progression in the subgroup of patients with severe gait freezing and balance disturbance who are suitable for this therapy is often more aggressive.⁸⁸ This means that long-term outcomes will be particularly important in gauging success of this intervention.

PPN DBS does not clearly improve other aspects of gait such as gait akinesia.⁴¹ Moreover, the evidence does not support any benefit for limb akinesia, rigidity, or tremor, and thus dopaminergic medication requirements do not substantially change after PPN DBS.^{12,13,23}

Regarding nonmotor symptoms, the current evidence does not strongly support any major impact on cognition outside of enhanced motor performance.⁵⁸ PPN DBS appears to increase REM sleep.⁸² Whether this increased REM sleep has any functional consequences, either beneficial or not, is unknown.

The clinically relevant question is whether PPN DBS can improve quality of life in patients with PD. So far, the available evidence supporting this ideal is very modest.^{12,16} It is clearly our hope that refinement of the clinical application of PPN DBS will yield the type of robust and consistent benefits seen with DBS of established targets in PD such as the STN and GPI. However, we acknowledge the less attractive possibility that the therapeutic action of the target itself may be the issue. For example, gait freezing is considered a complex deficit that involves dysfunction in widespread networks including attentional and motor systems, both cortical and brain stem. Relief of the latter may only have capacity to yield a circumscribed benefit. However, even if this were the case, there could still be an identifiable subgroup of patients where this benefit could improve quality of life and/or have a synergistic relationship with other emerging therapies. Of course, any benefit must be contrasted against risks of brain stem implantation.

So, what are the next steps? First, acknowledge that every centre has successes and failures. We need to identify what is different about patients who respond

positively and to identify the key predictors of therapeutic efficacy. To achieve this, we need to pool the experience of centres that implant the PPN. One initial approach would be a multicentre database capturing agreed measures of the clinical application (such as stimulation location) and outcomes. Only once the clinical methodology of PPN DBS has been further developed would it be appropriate to consider a multicenter randomized controlled trial to assess the impact on quality of life. ■

Acknowledgments: The Movement Disorders Society PPN DBS Working Group in collaboration with the World Society for Stereotactic and Functional Neurosurgery was supported by an unrestricted educational grant from Medtronic.

Appendix:

Following are the members of the PPN DBS Working Group: T. Aziz (United Kingdom); C. Blahak (Germany), B. Bloem (The Netherlands), P. Brown (United Kingdom), C. Butson (USA), S. Chabardes (France), T.J. Coyne (Australia), V. Czernecki (France), B. Debu (France), T. Foltynie (United Kingdom), E. Fonoff (Brazil), V. Fraix (France), K. Foote (USA), D. Grabli (France), C. Hamani (Canada), E.C. Hirsch (France), W. Hutchison (Canada), J.K. Krauss (Germany), C. Joint (United Kingdom), A.M. Lozano (Canada), P. Mazzone (Italy), E. Moro (France), M. Okun (USA), J. Ostrem (USA), N. Pavese (United Kingdom), C. Schrader (Germany), J. Stein (United Kingdom), C.-H. Tai (Taiwan), W. Thevathasan (Australia), I. Veletzas (Greece).

References

1. Jacobsohn L. Uber About the nuclei of the human brainstem: medulla oblongata, pons, and pedunculus cerebri. Attachment to the Proceedings of the Royal Prussian Academy of Science 1911.
2. Jenkinson N, Nandi D, Muthusamy K, et al. Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus. *Mov Disord* 2009;24(3):319-328.
3. Gut NK, Winn P. The pedunculopontine tegmental nucleus-A functional hypothesis from the comparative literature. *Mov Disord* 2016;31(5):615-624.
4. Garcia-Rill E, Houser CR, Skinner RD, Smith W, Woodward DJ. Locomotion-inducing sites in the vicinity of the pedunculopontine nucleus. *Brain Res Bull* 1987;18(6):731-738.
5. Winn P. Experimental studies of pedunculopontine functions: are they motor, sensory or integrative? *Parkinsonism Relat Disord* 2008;14(suppl 2):S194-S198.
6. Mena-Segovia J, Sims HM, Magill PJ, Bolam JP. Cholinergic brainstem neurons modulate cortical gamma activity during slow oscillations. *J Physiol* 2008;586(12):2947-2960.
7. Jenkinson N, Nandi D, Miall RC, Stein JF, Aziz TZ. Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey. *Neuroreport* 2004;15(17):2621-2624.
8. Nandi D, Aziz TZ, Giladi N, Winter J, Stein JF. Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus. *Brain* 2002;125(Pt 11):2418-2430.
9. Plaha P, Gill SS. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease. *Neuroreport* 2005;16(17):1883-1887.
10. Mazzone P, Lozano A, Stanzione P, et al. Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson's disease. *Neuroreport* 2005;16(17):1877-1881.

11. Fasano A, Aquino CC, Krauss JK, Honey CR, Bloem BR. Axial disability and deep brain stimulation in patients with Parkinson disease. *Nat Rev Neurol* 2015;11(2):98-110.
12. Ferraye MU, Debu B, Fraix V, et al. Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease. *Brain* 2009;133(Pt 1):205-214.
13. Moro E, Hamani C, Poon YY, et al. Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. *Brain* 2010;133(Pt 1):215-224.
14. Thevathasan W, Coyne TJ, Hyam JA, et al. Pedunculopontine nucleus stimulation improves gait freezing in Parkinson disease. *Neurosurgery* 2011;69(6):1248-1253.
15. Khan S, Gill SS, Mooney L, et al. Combined pedunculopontine-subthalamic stimulation in Parkinson disease. *Neurology* 2012;78(14):1090-1095.
16. Welter ML, Demain A, Ewencyk C, et al. PPNa-DBS for gait and balance disorders in Parkinson's disease: a double-blind, randomised study. *J Neurol* 2015;262(6):1515-1525.
17. Hamani C, Aziz T, Bloem BR, et al. Pedunculopontine nucleus region deep brain stimulation in Parkinson disease: surgical anatomy and terminology. *Stereotact Funct Neurosurg* 2016;94(5):298-306.
18. Hamani C, Lozano AM, Mazzone PA, et al. Pedunculopontine nucleus region deep brain stimulation in Parkinson disease: surgical techniques, side effects, and postoperative imaging. *Stereotact Funct Neurosurg* 2016;94(5):307-319.
19. Benabid AL, Deuschl G, Lang AE, Lyons KE, Reza AR. Deep brain stimulation for Parkinson's disease. *Mov Disord* 2006;21(suppl 14):S168-S170.
20. Moro E, Albanese A, Krauss JK, Metman LV, Vidailhet M, Hariz MI. Guest editors' introduction. *Mov Disord* 2011;26(suppl 1):S1-S2.
21. Linstone HA, and Murray Turoff, eds. *The Delphi Method: Techniques and Applications*. Reading, MA: Addison-Wesley, 1975.
22. Stefani A, Lozano AM, Peppe A, et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. *Brain* 2007;130(Pt 6):1596-1607.
23. Thevathasan W, Silburn PA, Brooker H, et al. The impact of low-frequency stimulation of the pedunculopontine nucleus region on reaction time in parkinsonism. *J Neurol Neurosurg Psychiatry* 2010;81(10):1099-1104.
24. Pereira EA, Muthusamy KA, De Pennington N, Joint CA, Aziz TZ. Deep brain stimulation of the pedunculopontine nucleus in Parkinson's disease. Preliminary experience at Oxford. *Br J Neurosurg* 2008;22(suppl 1):S41-S44.
25. Schrader C, Seehaus F, Capelle HH, Windhagen A, Windhagen H, Krauss JK. Effects of pedunculopontine area and pallidal DBS on gait ignition in Parkinson's disease. *Brain Stim* 2013;6(6):856-859.
26. Liu HG, Zhang K, Yang AC, Zhang JG. Deep brain stimulation of the subthalamic and pedunculopontine nucleus in a patient with Parkinson's disease. *J Korean Neurosurg Soc* 2015;57(4):303-306.
27. Yousif N, Bhatt H, Bain PG, Nandi D, Seemungal BM. The effect of pedunculopontine nucleus deep brain stimulation on postural sway and vestibular perception. *Eur J Neurol* 2016;23(3):668-670.
28. Zrinzo L, Zrinzo LV, Tisch S, et al. Stereotactic localization of the human pedunculopontine nucleus: atlas-based coordinates and validation of a magnetic resonance imaging protocol for direct localization. *Brain* 2008;131(Pt 6):1588-1598.
29. Kringelbach ML, Jenkinson N, Owen SL, Aziz TZ. Translational principles of deep brain stimulation. *Nat Rev Neurosci* 2007;8(8):623-635.
30. Giladi N, McDermott MP, Fahn S, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. *Neurology* 2001;56(12):1712-1721.
31. Scelzo E, Lozano AM, Hamani C, et al. Pedunculopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. *J Neurol Neurosurg Psychiatry* 2017.
32. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. *N Engl J Med* 2006;355(9):896-908.
33. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. *N Engl J Med* 2010;362(22):2077-2091.
34. Ferraye MU, Debu B, Fraix V, et al. Subthalamic nucleus versus pedunculopontine nucleus stimulation in Parkinson disease: synergy or antagonism? *J Neural Transm* 2011;118(10):1469-1475.
35. Nosko D, Ferraye MU, Fraix V, et al. Low-frequency versus high-frequency stimulation of the pedunculopontine nucleus area in Parkinson's disease: a randomised controlled trial. *J Neurol Neurosurg Psychiatry* 2015;86(6):674-679.
36. Zrinzo L, Zrinzo LV, Hariz M. The peripeduncular nucleus: a novel target for deep brain stimulation? *Neuroreport* 2007;18(12):1301-1302.
37. Thevathasan W, Pogossyan A, Hyam JA, et al. Alpha oscillations in the pedunculopontine nucleus correlate with gait performance in parkinsonism. *Brain* 2012;135(Pt 1):148-160.
38. Yelnik J. PPN or PPD, what is the target for deep brain stimulation in Parkinson's disease? *Brain* 2007;130(Pt 9):e79; author reply e80.
39. Tattersall TL, Stratton PG, Coyne TJ, et al. Imagined gait modulates neuronal network dynamics in the human pedunculopontine nucleus. *Nat Neurosci* 2014;17(3):449-454.
40. Fu RZ, Naushahi MJ, Adams A, et al. Sub-caudal pedunculopontine nucleus (PPN) deep brain stimulation (DBS) best predicts improvements in freezing of gait questionnaire (FOGQ) scores in Parkinson's disease patients. *Mov Disord* 29(suppl 1):1193-2014.
41. Thevathasan W, Cole MH, Graepel CL, et al. A spatiotemporal analysis of gait freezing and the impact of pedunculopontine nucleus stimulation. *Brain* 2012;135(Pt 5):1446-1454.
42. Mestre TA, Sidiropoulos C, Hamani C, et al. Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson's disease. *Mov Disord* 2016;31(10):1570-1574.
43. Fahn S, Elton RL. UPDRS Program Members. Unified Parkinson's Disease Rating Scale In: Fahn S MC, Goldstein M, Calne DB, eds. *Recent Developments in Parkinson's Disease*. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163, 293-304.
44. Munhoz RP, Li JY, Kurtinecz M, et al. Evaluation of the pull test technique in assessing postural instability in Parkinson's disease. *Neurology* 2004;62(1):125-127.
45. Giladi N, Shabtai H, Simon ES, Biran S, Tal J, Korczyn AD. Construction of freezing of gait questionnaire for patients with Parkinsonism. *Parkinsonism Relat Disord* 2000;6(3):165-170.
46. Giladi N, Tal J, Azulay T, et al. Validation of the freezing of gait questionnaire in patients with Parkinson's disease. *Mov Disord* 2009;24(5):655-661.
47. Chee R, Murphy A, Danoudis M, Georgiou-Karistianis N, Iansek R. Gait freezing in Parkinson's disease and the stride length sequence effect interaction. *Brain* 2009;132(Pt 8):2151-2160.
48. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). *Mov Disord* 1999;14(4):572-584.
49. Koop MM, Andrzejewski A, Hill BC, Heit G, Bronte-Stewart HM. Improvement in a quantitative measure of bradykinesia after microelectrode recording in patients with Parkinson's disease during deep brain stimulation surgery. *Mov Disord* 2006;21(5):673-678.
50. Khan S, Mooney L, Plaha P, et al. Outcomes from stimulation of the caudal zona incerta and pedunculopontine nucleus in patients with Parkinson's disease. *Br J Neurosurg* 2011;25(2):273-280.
51. Moreau C, Defebvre L, Destee A, et al. STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. *Neurology* 2008;71(2):80-84.
52. Hazrati LN, Wong JC, Hamani C, et al. Clinicopathological study in progressive supranuclear palsy with pedunculopontine stimulation. *Mov Disord* 2012;27(10):1304-1307.
53. Acar F, Acar G, Bir LS, Gedik B, Oguzhanoglu A. Deep brain stimulation of the pedunculopontine nucleus in a patient with freezing of gait. *Stereotact Funct Neurosurg* 2011;89(4):214-219.
54. Jenkinson N, Brittain JS, Hicks SL, Kennard C, Aziz TZ. On the origin of oscillopsia during pedunculopontine stimulation. *Stereotact Funct Neurosurg* 2012;90(2):124-129.
55. Aviles-Olmos I, Foltynie T, Panicker J, et al. Urinary incontinence following deep brain stimulation of the pedunculopontine nucleus. *Acta Neurochir (Wien)* 2011;153(12):2357-2360.
56. Khan S, Javed S, Mooney L, et al. Clinical outcomes from bilateral versus unilateral stimulation of the pedunculopontine nucleus with

- and without concomitant caudal zona incerta region stimulation in Parkinson's disease. *Br J Neurosurg* 2012;26(5):722-725.
57. Mazzone P, Paoloni M, Mangone M, et al. Unilateral deep brain stimulation of the pedunculopontine tegmental nucleus in idiopathic Parkinson's disease: effects on gait initiation and performance. *Gait Posture* 2014;40(3):357-362.
 58. Thevathasan W, Pogosyan A, Hyam JA, et al. A block to pre-prepared movement in gait freezing, relieved by pedunculopontine nucleus stimulation. *Brain* 2011;134(Pt 7):2085-2095.
 59. Peppe A, Pierantozzi M, Chiavalon C, et al. Deep brain stimulation of the pedunculopontine tegmentum and subthalamic nucleus: effects on gait in Parkinson's disease. *Gait Posture* 2010;32(4):512-518.
 60. Faist M, Xie J, Kurz D, et al. Effect of bilateral subthalamic nucleus stimulation on gait in Parkinson's disease. *Brain* 2001;124(Pt 8):1590-1600.
 61. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* 2008;23(15):2129-2170.
 62. Shih LC, Vanderhorst VG, Lozano AM, Hamani C, Moro E. Improvement of pisa syndrome with contralateral pedunculopontine stimulation. *Mov Disord* 2013;28(4):555-556.
 63. Ricciardi L, Piano C, Bentivoglio AR, Fasano A. Long-term effects of pedunculopontine nucleus stimulation for Pisa syndrome. *Parkinsonism Relat Disord* 2014;20(12):1445-1446.
 64. Doherty KM, van de Warrenburg BP, Peralta MC, et al. Postural deformities in Parkinson's disease. *Lancet Neurol* 2011;10(6):538-549.
 65. Mazzone P, Padua L, Falisi G, Insola A, Florio TM, Scarnati E. Unilateral deep brain stimulation of the pedunculopontine tegmental nucleus improves oromotor movements in Parkinson's disease. *Brain Stim* 2012;5(4):634-641.
 66. Zanini S, Moschella V, Stefani A, et al. Grammar improvement following deep brain stimulation of the subthalamic and the pedunculopontine nuclei in advanced Parkinson's disease: a pilot study. *Parkinsonism Relat Disord* 2009;15(8):606-609.
 67. Pinto S, Ferraye M, Espesser R, et al. Stimulation of the pedunculopontine nucleus area in Parkinson's disease: effects on speech and intelligibility. *Brain* 2014;137(Pt 10):2759-2772.
 68. Temel Y, Blokland A, Ackermans L, et al. Differential effects of subthalamic nucleus stimulation in advanced Parkinson disease on reaction time performance. *Exp Brain Res* 2006;169(3):389-399.
 69. Brown RG, Dowsey PL, Brown P, et al. Impact of deep brain stimulation on upper limb akinesia in Parkinson's disease. *Ann Neurol* 1999;45(4):473-488.
 70. Nandi D, Liu X, Winter JL, Aziz TZ, Stein JF. Deep brain stimulation of the pedunculopontine region in the normal non-human primate. *J Clin Neurosci* 2002;9(2):170-174.
 71. Fischer J, Schwiecker K, Bittner V, et al. Modulation of attentional processing by deep brain stimulation of the pedunculopontine nucleus region in patients with parkinsonian disorders. *Neuropsychology* 2015;29(4):632-637.
 72. Camicioli R, Oken BS, Sexton G, Kaye JA, Nutt JG. Verbal fluency task affects gait in Parkinson's disease with motor freezing. *J Geriatr Psychiatry Neurol* 1998;11(4):181-185.
 73. Giladi N, Hausdorff JM. The role of mental function in the pathogenesis of freezing of gait in Parkinson's disease. *J Neurol Sci* 2006;248(1-2):173-176.
 74. Costa A, Carlesimo GA, Caltagirone C, et al. Effects of deep brain stimulation of the pedunculopontine area on working memory tasks in patients with Parkinson's disease. *Parkinsonism Relat Disord* 2010;16(1):64-67.
 75. Alessandro S, Ceravolo R, Brusa L, et al. Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: focus on sleep and cognitive domains. *J Neurol Sci* 2010;289(1-2):44-48.
 76. Ricciardi L, Piano C, Rita Bentivoglio A, Fasano A. Pedunculopontine nucleus stimulation in Parkinson's disease dementia. *Biol Psychiatry* 2015;77(8):e35-e40.
 77. Ceravolo R, Brusa L, Galati S, et al. Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in parkinsonian patients. *Eur J Neurol* 2011;18(6):842-849.
 78. Ballanger B, Lozano AM, Moro E, et al. Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: a [(15)O] H₂O PET study. *Hum Brain Mapp* 2009;30(12):3901-3909.
 79. Strafella AP, Lozano AM, Ballanger B, Poon YY, Lang AE, Moro E. rCBF changes associated with PPN stimulation in a patient with Parkinson's disease: a PET study. *Mov Disord* 2008;23(7):1051-1054.
 80. Romigi A, Placidi F, Peppe A, et al. Pedunculopontine nucleus stimulation influences REM sleep in Parkinson's disease. *Eur J Neurol* 2008;15(7):e64-e65.
 81. Arnulf I, Ferraye M, Fraix V, et al. Sleep induced by stimulation in the human pedunculopontine nucleus area. *Ann Neurol* 2010;67(4):546-549.
 82. Lim AS, Moro E, Lozano AM, et al. Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. *Ann Neurol* 2009;66(1):110-114.
 83. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. *Nature* 2005;437(7063):1257-1263.
 84. Lim AS, Lozano AM, Moro E, et al. Characterization of REM-sleep associated ponto-geniculo-occipital waves in the human pons. *Sleep* 2007;30(7):823-827.
 85. Peeraully T, Yong MH, Chokroverty S, Tan EK. Sleep and Parkinson's disease: a review of case-control polysomnography studies. *Mov Disord* 2012;27(14):1729-1737.
 86. Plihal W, Born J. Effects of early and late nocturnal sleep on declarative and procedural memory. *J Cogn Neurosci* 1997;9(4):534-547.
 87. Piallat B, Chabardes S, Torres N, et al. Gait is associated with an increase in tonic firing of the sub-cuneiform nucleus neurons. *Neuroscience* 2009;158(4):1201-1205.
 88. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. *Brain* 2009;132(Pt 11):2947-2957.